Healthcare · Biotechnology
Price
$1.28
Market Cap
$7.5M
Employees
75
Beta
1.04
Avg Volume
300,237
CEO
Cameron Reynolds
Business Description
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.29
Stock Price: $1.28
EPS (Diluted): -4.40
EPS (Diluted): -4.40
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.80
Stock Price: $1.28
Total Equity: -$34.25M
Shares: 5,341,607
Total Equity: -$34.25M
Shares: 5,341,607
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.90
Market Cap: $7.50M
Total Debt: $10.57M
Cash: $1.12M
EBITDA: -$19.80M
Total Debt: $10.57M
Cash: $1.12M
EBITDA: -$19.80M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$37.6M
Market Cap: $7.50M
Total Debt: $10.57M
Cash: $1.12M
Total Debt: $10.57M
Cash: $1.12M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
15.80
Stock Price: $1.28
Revenue: $1.73M
Shares: 5,341,607
Revenue: $1.73M
Shares: 5,341,607
EV/Sales (Total value vs revenue — works when P/E can't)
API21.79
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $1.73M
Revenue: $1.73M
Revenue: $1.73M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,228.6%
Operating Income: -$21.22M
Revenue: $1.73M
Revenue: $1.73M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,352.2%
Net Income: -$23.36M
Revenue: $1.73M
Revenue: $1.73M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
68.2%
Net Income: -$23.36M
Total Equity: -$34.25M
Total Equity: -$34.25M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
85.6%
Operating Income: -$21.22M
Tax Rate: 0.0%
Equity: -$34.25M
Total Debt: $10.57M
Cash: $1.12M
Tax Rate: 0.0%
Equity: -$34.25M
Total Debt: $10.57M
Cash: $1.12M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.17
Current Assets: $2.06M
Current Liabilities: $12.23M
Current Liabilities: $12.23M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.31
Short-Term Debt: $3.31M
Long-Term Debt: $7.26M
Total Debt: $10.57M
Total Equity: -$34.25M
Long-Term Debt: $7.26M
Total Debt: $10.57M
Total Equity: -$34.25M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.32
Revenue: $1.73M
Shares: 5,341,607
Shares: 5,341,607
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-6.41
Total Equity: -$34.25M
Shares: 5,341,607
Shares: 5,341,607
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.70
Operating CF: -$19.68M
CapEx: -$89,558
Shares: 5,341,607
CapEx: -$89,558
Shares: 5,341,607
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.28
Stock Price: $1.28
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$23.36M
Net Income: -$23.36M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VNRX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 2:35am (6h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $90,035 | $306,392 | $775,302 | $1.2M | $1.7M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $90,035 | $306,392 | $775,302 | $1.2M | $1.7M |
| Operating Expenses | $28.4M | $32.1M | $36.8M | $28.3M | $22.9M |
| Operating Income | -$28.3M | -$31.8M | -$36.0M | -$27.0M | -$21.2M |
| Net Income | -$26.8M | -$30.3M | -$35.3M | -$27.0M | -$23.4M |
| EBITDA | -$25.7M | -$29.2M | -$34.0M | -$25.6M | -$19.8M |
| EPS | $-10.20 | $-11.00 | $-10.00 | $-6.20 | $-4.40 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 2:35am (6h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $20.6M | $10.9M | $20.7M | $3.3M | $1.1M |
| Total Current Assets | $22.0M | $12.2M | $21.9M | $4.1M | $2.1M |
| Total Assets | $27.5M | $18.3M | $28.0M | $9.4M | $6.9M |
| Current Liabilities | $6.5M | $17.4M | $8.9M | $7.8M | $12.2M |
| Long-Term Debt | $2.3M | $2.8M | $3.6M | $4.0M | $7.3M |
| Total Liabilities | $9.8M | $21.4M | $36.7M | $35.5M | $42.5M |
| Total Equity | $17.9M | -$2.6M | -$7.8M | -$24.9M | -$34.2M |
| Retained Earnings | -$137.0M | -$167.3M | -$202.6M | -$229.5M | -$252.9M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 2:35am (6h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$20.9M | -$15.3M | -$18.1M | -$25.9M | -$19.7M |
| Capital Expenditure | $-973,559 | -$1.6M | -$1.1M | $-573,852 | $-89,558 |
| Free Cash Flow | -$21.8M | -$16.8M | -$19.1M | -$26.5M | -$19.8M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $-31,772 | $0 | $0 |
| Net Change in Cash | $1.1M | -$9.7M | $9.9M | -$17.5M | -$2.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 2:35am (6h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$7.9M $5.3M – $11.6M
|
$21.8M $16.8M – $28.4M
|
$56.0M $43.3M – $73.1M
|
$82.8M $63.9M – $108.0M
|
| EBITDA |
-$7.9M -$11.6M – -$5.3M
|
-$21.8M -$28.4M – -$16.8M
|
-$56.0M -$73.1M – -$43.3M
|
-$82.8M -$108.0M – -$63.9M
|
| Net Income |
-$6.4M -$8.5M – -$4.3M
|
-$3.4M -$6.8M – $-36,172
|
$3.6M $2.6M – $5.1M
|
$7.1M $5.0M – $10.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 2:35am (6h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +240.3% | +153.0% | +59.1% | +40.0% |
| Gross Profit Growth | +240.3% | +153.0% | +59.1% | +40.0% |
| Operating Income Growth | -12.2% | -13.2% | +24.9% | +21.5% |
| Net Income Growth | -12.9% | -16.7% | +23.6% | +13.4% |
| EBITDA Growth | -13.8% | -16.4% | +24.9% | +22.6% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VNRX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VNRX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30